6562 Stock Overview
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
UBI Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$13.70 |
| 52 Week High | NT$42.54 |
| 52 Week Low | NT$10.00 |
| Beta | 0.20 |
| 1 Month Change | -53.48% |
| 3 Month Change | -58.80% |
| 1 Year Change | -66.27% |
| 3 Year Change | n/a |
| 5 Year Change | -45.95% |
| Change since IPO | -85.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6562 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -49.4% | -1.1% | -0.6% |
| 1Y | -66.3% | -21.5% | 29.2% |
Return vs Industry: 6562 underperformed the TW Biotechs industry which returned -23.7% over the past year.
Return vs Market: 6562 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6562 volatility | |
|---|---|
| 6562 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6562's share price has been volatile over the past 3 months.
Volatility Over Time: 6562's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Chei-Hsiang Chen | www.ubi-pharma.com |
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion.
UBI Pharma Inc. Fundamentals Summary
| 6562 fundamental statistics | |
|---|---|
| Market cap | NT$1.62b |
| Earnings (TTM) | NT$803.00k |
| Revenue (TTM) | NT$648.63m |
2,016x
P/E Ratio2.5x
P/S RatioIs 6562 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6562 income statement (TTM) | |
|---|---|
| Revenue | NT$648.63m |
| Cost of Revenue | NT$451.50m |
| Gross Profit | NT$197.12m |
| Other Expenses | NT$196.32m |
| Earnings | NT$803.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0068 |
| Gross Margin | 30.39% |
| Net Profit Margin | 0.12% |
| Debt/Equity Ratio | 7.9% |
How did 6562 perform over the long term?
See historical performance and comparison